(Press-News.org) Contact information: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Parasite lost
By targeting enzyme in mosquito-borne parasite, researchers aim to eliminate malaria
Using advanced methodologies that pit drug compounds against specific types of malaria parasite cells, an international team of scientists, including researchers at the University of California, San Diego School of Medicine and the Genomics Institute of the Novartis Research Foundation, have identified a potential new weapon and approach for attacking the parasites that cause malaria.
Their findings are published in the November 27, 2013 advanced online publication of Nature.
Despite advances in prevention and treatment in recent years, malaria remains one of the world's great infectious scourges. In 2010, according to the World Health Organization, there were an estimated 219 million cases globally and 660,000 deaths, mostly among African children.
The disease is caused by Plasmodium parasites, which are transmitted to humans by the infectious bite of an Anopheles mosquito. Plasmodium vivax and Plasmodium falciparum are the most problematic of the parasite species. The former is the most widespread globally; the latter most deadly.
Principal investigator Elizabeth A. Winzeler, PhD, professor in the Division of Pharmacology and Drug Discovery, Department of Pediatrics and director of translational research at the UC San Diego Health Sciences Center for Immunity, Infection & Inflammation, and colleagues found a key metabolic enzyme (phosphatidylinositol 4-kinase or PI4K) that is used for intracellular development by Plasmodium species at each stage of infection in the vertebrate host.
The discovery could have significant ramifications for eventually eradicating malaria as a global disease. "Elimination efforts are more effective with better tools and infrastructure," said Winzeler. "Clearly we have better infrastructure and communication now than we had in the 1960s. To make more progress, though, we need more effective drugs."
A major obstacle has been the developmental nature of the P. vivax parasite. While some antimalarial drugs effectively kill P. vivax as it circulates in the host's bloodstream, the parasite also produces an early-stage form called a hypnozoite that can lie dormant and undetected in the livers of infected persons for years before reinitiating development and triggering relapse.
"Most drugs selectively work on certain stages of the (parasite) lifecycle, but not all stages," said Case McNamara, PhD, the study's first author and a researcher at the Genomics Institute of the Novartis Research Foundation in San Diego. "Therefore, inhibitors of this drug target have the potential to not only cure individuals of a malaria infection, but to also prevent infections and even block transmission of the parasite back to the mosquito."
Currently, the only licensed antimalarial drug capable of fully cleansing hidden hypnozoites and eliminating the possibility of relapse – known as the "radical cure" – is primaquine, a drug first tested in the 1940s and licensed by the Food and Drug Administration in 1952.
But primaquine has significant adverse side effects and shortcomings, according to Winzeler, most notably that it can cause life-threatening anemia in people with a specific inherited metabolic enzyme deficiency frequently found in malaria-endemic regions.
"In addition, it may not work all of the time and it requires a prolonged dosing schedule, up to 14 days, which means compliance is an issue. People often do not take the full dose," Winzeler said. "Primaquine is an old drug and it's not clear that it would ever be licensed in today's regulatory environment."
Primaquine was developed "by simply injecting a lot of compounds into monkeys and seeing which compound cured malaria infections," said Winzeler. It was later tested in humans using prisoners.
The new approach is far more finely tuned, based on a series of detailed cellular assays that seek to model different parasite lifecycle stages in miniature test tubes. The researchers looked for the rare compound class that had activities in all parasite stages, but no activity against human cells and which was also drug-like. A new chemical class, called imidazopyrazines, possessed these properties. The researchers then identified the protein target of these compounds as PI4K.
"(Dr. Winzeler) had a very creative and powerful idea to help identify malaria drug targets," said McNamara. "By patiently evolving drug-resistant parasites against the drug of interest, we can probe the genome for the changes responsible for conferring resistance.
"Fortunately, malaria parasites will often try to alter the drug target in subtle ways to prevent the drug from working effectively. So, by identifying these changes we, in turn, identify the drug target. This approach has worked so well that it has quickly become a standard technique in our field to help study and characterize all new antimalarials."
Because PI4K is also found in humans, Winzeler said the next challenge is to develop a superior drug that continues to discriminate between the parasite and human versions of this enzyme. “Since we know the identity of this protein and will hopefully soon solve its structure, this task will be much easier,” she said.”
INFORMATION:
Co-authors include Marcus C.S. Lee, Santha Kumar and Philipp P. Henrich, Department of Microbiology & Immunology, Columbia University; Chek Shik Lim, Siau Hoi Lim, Oliver Simon, Bryan K.S. Yeung, Christophe Bodenreider and Thierry T. Diagana, Novartis Institutes for Tropical Disease, Singapore; Jason Roland, Arnab K. Chatterjee, Susan L. McCormack, Kerstin Gagaring, Maureen Ibanez, Nobutaka Kato, Kelli L. Kuhen, Advait Nagle, David M. Plouffe, Badry Bursulaya, David C. Tully and Richard J. Glynne, Genomics Institute of the Novartis Research Foundation, San Diego; Micah J. Manary and Stephan Meister, Department of Pediatrics, UCSD; Anne-Marie Zeeman and Clemens H.M. Kocken, Department of Parasitology, Biomedical Primate Research Centre, The Netherlands; Koen J. Dechering and Martijn Timmerman, TropIQ Health Sciences, The Netherlands; Christoph Fischeli, Swiss Tropical and Public Health Institute; Mathias Rottmann, Swiss Tropical and Public Health Institute and University of Basel; Lucia Rameh, Department of Medicine, Boston University; Joerg Trappe and Dorothea Haasen, Novartis Institutes for BioMedical Research; Robert W. Sauerwein, TropIQ Health Sciences and Department of Medical Microbiology, Radboud University, The Netherlands; Rossarin Suwanarusk and Laurent Renia, Laboratory of Malaria Immunology, Agency for Science Technology and Research, Singapore; Bruce Russell, Laboratory of Malaria Immunology, Agency for Science Technology and Research and Department of Microbiology, National University of Singapore; Francois Nosten, Centre for Tropical Medicine, University of Oxford and Shoklo Malaria Research Unite, Mahidol University, Thailand; and David A. Fidock, Department of Microbiology & Immunology, Columbia University and Division of Infectious Diseases, Columbia University Medical Center, NY.
Funding support came, in part, from the Wellcome Trust, the Medicines for Malaria Venture, the Swiss Tropical and Public Health Institute, Columbia University, the Novartis Institute for Tropical Diseases, the Singapore Immunology Network and Horizontal Programme on Infectious Diseases under the Agency for Science Technology and Research, the Bill and Melinda Gates Foundation and the National Institutes of Health (grants R01AI090141, R01085584 and R01079709).
Parasite lost
By targeting enzyme in mosquito-borne parasite, researchers aim to eliminate malaria
2013-11-28
ELSE PRESS RELEASES FROM THIS DATE:
Economic development can only buy happiness up to a 'sweet spot' of $36,000 GDP per person, study finds
2013-11-28
Economic development can only buy happiness up to a 'sweet spot' of $36,000 GDP per person, study finds
Economists have shed light on the vexed question of whether economic development can buy happiness – and it seems that life satisfaction actually dips ...
Scientists develop way to successfully give nanoparticle therapeutics orally
2013-11-28
Scientists develop way to successfully give nanoparticle therapeutics orally
Findings will allow for more targeted, convenient drug delivery to treat chronic diseases, like diabetes
Boston, MA – Pop a pill or be poked by a ...
Making a gem of a tiny crystal
2013-11-28
Making a gem of a tiny crystal
Slowly cooled DNA transforms disordered nanoparticles into orderly crystal
Nature builds flawless diamonds, sapphires and other gems. Now a Northwestern University research team is the first to build near-perfect single crystals ...
The good news about the global epidemic of dementia
2013-11-28
The good news about the global epidemic of dementia
New England Journal of Medicine perspective highlights effects of education, prevention
SEATTLE—It's rare to hear good news about dementia. But that's what a New England Journal of Medicine Perspective article ...
Physicists find a way to study coldest objects in the universe
2013-11-28
Physicists find a way to study coldest objects in the universe
They are the coldest objects in the Universe and are so fragile that even a single photon can heat and destroy them.
Known as Bose-Einstein condensates (BECs) and consisting of just a cluster ...
Improved safety measures by mental health service providers help to reduce suicide rates
2013-11-28
Improved safety measures by mental health service providers help to reduce suicide rates
Mental health service providers looking after patients at risk of suicide need to reduce absconding on in-patient wards and boost specialist community services ...
Global study reveals pandemic of untreated cancer pain due to over-regulation of pain medicines
2013-11-28
Global study reveals pandemic of untreated cancer pain due to over-regulation of pain medicines
A ground-breaking international collaborative survey, published today in Annals of Oncology, shows that more than half of the world's population live in countries where ...
Are you carrying adrenal Cushing's syndrome without knowing it?
2013-11-28
Are you carrying adrenal Cushing's syndrome without knowing it?
In light of new research, Dr. Andre Lacroix suggests genetic screening to find 'silent carriers'
Genetic research that will be published tomorrow in the New England Journal of Medicine ...
Pills of the future: Nanoparticles
2013-11-28
Pills of the future: Nanoparticles
CAMBRIDGE, MA -- Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so ...
New research shows pre-existing diabetes in pregnancy greatly increases the risk of death of the fetus or infant child
2013-11-28
New research shows pre-existing diabetes in pregnancy greatly increases the risk of death of the fetus or infant child
New research shows that pre-existing diabetes in pregnant women greatly increases the risk of death of their unborn fetus by around four-and-a-half ...
LAST 30 PRESS RELEASES:
Can’t sleep? Insomnia associated with accelerated brain aging
Study links teacher turnover to higher rates of student suspensions, disciplinary referrals
How harmful bacteria hijack crops
Crowded conditions muddle frogs’ mating choices
A new way to guide light, undeterred
Researchers uncover how COVID-19 may linger in cancer patients and affect treatment outcomes
Tiny metal figurines from Sardinia's Nuragic civilization in around 1,000 BC reveal extensive ancient Mediterranean metal trading networks
Natural microfibers may degrade differently to synthetic materials under simulated sunlight exposure in freshwater and seawater conditions, with implications for how such pollutants affect aquatic lif
Indian new mums report better postpartum wellbeing when their own mum acts as their primary support - while women whose mother-in-law is the primary caregiver instead report significantly lower overal
Young adult intelligence and education are correlated with socioeconomic status in midlife
Traditional and “existential” wellness vary significantly between US regions
Smartwatches detect early signs of PTSD among those watching coverage of the Oct 7 attacks in Israel
The pandemic may have influenced the trainability of dogs, as reported by their owners
The withdrawal of U.S. funding for tuberculosis could lead to up to 2.2 million additional deaths between 2025 and 2030 inclusive
A ‘universal’ therapy against the seasonal flu? Antibody cocktail targets virus weak spot
Could robots help kids conquer reading anxiety? New study from the Department of Computer Science at UChicago suggests so
UCSB-designed soft robot intubation device could save lives
Burial Site challenges stereotypes of Stone Age women and children
Protein found in the eye and blood significantly associated with cognition scores
USF study reveals how menopause impacts women’s voices – and why it matters
AI salespeople aren’t better than humans… yet
Millions of men could benefit from faster scan to diagnose prostate cancer
Simulations solve centuries-old cosmic mystery – and discover new class of ancient star systems
MIT study explains how a rare gene variant contributes to Alzheimer’s disease
Race, ethnicity, insurance payer, and pediatric cardiac arrest survival
High-intensity exercise and hippocampal integrity in adults with cannabis use disorder
“Brain dial” for consumption found in mice
Lung cancer rewires immune cells in the bone marrow to weaken body’s defenses
Researchers find key to Antarctic ice loss blowing in the north wind
Ten years after the discovery, gravitational waves verify Stephen Hawking's Black Hole Area Theorem
[Press-News.org] Parasite lostBy targeting enzyme in mosquito-borne parasite, researchers aim to eliminate malaria